Nature子刊：华人学者开发巨噬细胞增强型类器官

Core Viewpoint - The research led by Professor Pan Qiwei from Erasmus University Medical Center focuses on developing macrophage-augmented organoids (MaugO) that replicate the complex pathophysiology of viral diseases, aiding in the development of multitarget therapeutics [1][6]. Group 1: Research Background - The study addresses the complexity of acute viral disease pathophysiology, characterized by strong inflammatory responses driven by immune cells, leading to tissue damage [5]. - Current in vitro models primarily replicate the viral life cycle but fail to simulate immune cell-mediated disease mechanisms [5]. Group 2: Development of MaugO - The research team integrated macrophages into primary organoids cultured from human liver tissue to construct MaugO [6]. - MaugO was tested for infections from two RNA viruses (Hepatitis E virus and SARS-CoV-2) and one DNA virus (monkeypox virus), all of which can infect and affect human liver [8]. Group 3: Findings and Implications - MaugO successfully replicated the infections and the resulting inflammatory responses across all three acute viral infection models, albeit with varying degrees [8]. - The study demonstrated the multifunctional role of human bile in the replication of Hepatitis E virus and the inflammatory response [8]. - MaugO also exhibited characteristics of inflammatory cell death induced by Hepatitis E virus infection when integrated with pro-inflammatory macrophages [8]. - The research validated the concept of developing multitarget therapies that can simultaneously address the virus, inflammatory response, and the resultant inflammatory cell death [8].